公开(公告)号：EP0542931A1

公开(公告)日：1993-05-26

申请号：EP92903763.0

申请日：1991-08-06

申请人： GENENTECH, INC.

发明人： ABRAHMSEN, Lars ,  BURNIER, John ,  WELLS, James, A.

IPC分类号： C12N1 ,  C07K14 ,  C12N9 ,  C12N15 ,  C12P21 ,  C12R1

CPC分类号： C12N9/54 ,  C07K14/61 ,  C12N9/22 ,  C12P21/02

摘要： L'invention se rapporte à des variantes de sérine-protéases dérivées de sérine-protéases précurseurs à l'aide de procédés recombinants et/ou chimiques permettant de former des variantes de protéases présentant une activité de ligase peptidique améliorée. L'invention comprend des nouveaux substrats de ligation qui, en combinaison avec les variantes de sérine-protéases et un deuxième substrat de liaison, sont capables de former un produit de ligation. L'invention se rapporte également à des procédés permettant de former de tels produits de ligation et aux produits ainsi formés.

公开(公告)号：EP0728147A1

公开(公告)日：1996-08-28

申请号：EP95901112.0

申请日：1994-11-04

申请人： GENENTECH, INC.

发明人： LOWE, David ,  CUNNINGHAM, Brian, C. ,  OARE, David ,  McDOWELL, Robert, S. ,  BURNIER, John

IPC分类号： C12N15 ,  A61K38 ,  A61P1 ,  A61P3 ,  A61P7 ,  A61P9 ,  A61P13 ,  A61P15 ,  C07H21 ,  C07K14 ,  C12P21 ,  C12R1

CPC分类号： C07K14/58 ,  A61K38/00

摘要： Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

公开(公告)号：EP0728147B1

公开(公告)日：2003-02-12

申请号：EP95901112.3

申请日：1994-11-04

申请人： GENENTECH, INC.

发明人： LOWE, David ,  CUNNINGHAM, Brian, C. ,  OARE, David ,  McDOWELL, Robert, S. ,  BURNIER, John

IPC分类号： C07K14/58 ,  C12N15/12 ,  A61K38/22

CPC分类号： C07K14/58 ,  A61K38/00

摘要： Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

公开(公告)号：EP0542931B1

公开(公告)日：1999-12-08

申请号：EP92903763.8

申请日：1991-08-06

申请人： GENENTECH, INC.

发明人： ABRAHMSEN, Lars ,  BURNIER, John ,  WELLS, James, A.

IPC分类号： C12N15/57 ,  C12N9/54 ,  C12N9/56 ,  C12P21/02

CPC分类号： C12N9/54 ,  C07K14/61 ,  C12N9/22 ,  C12P21/02

摘要： The invention relates to serine protease variants derived from precursor serine proteases via recombinant and/or chemical methods to form protease variants having improved peptide ligase activity. The invention also includes novel ligation substrates which in combination with the serine protease variants and a second ligation substrate are capable of forming a ligation product. The invention also relates to methods for forming such ligation products and the products formed thereby.